Brief: Protagonist Therapeutics Inc Closing Of Worldwide Collaboration And License Agreement For Rusfertide With Takeda
18/03/2024 11:27
March 18 (Reuters) - Takeda Pharmaceutical Co Ltd
4502.T :
* PROTAGONIST THERAPEUTICS INC: CLOSING OF WORLDWIDE
COLLABORATION
AND LICENSE AGREEMENT FOR RUSFERTIDE WITH TAKEDA
* PROTAGONIST THERAPEUTICS INC: CO WILL RECEIVE $300 MILLION
UPFRONT PAYMENT ASSOCIATED WITH TRANSACTION IN Q2 OF 2024
Further company coverage: 4502.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary